Investigational therapies for Ewing sarcoma: a search without a clear finding

References

• Paulussen M, Bielack S, Jürgens H, et al. ESMO Guidelines Working Group. Ewing’s sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20(Suppl 4):140–142.
   PubMed Web of Science ®Google Scholar
• Dahlin DC, Coventry MB, Scanlon PW. Ewing’s sarcoma: a critical analysis of 165 cases. J Bone Joint Surg Am. 1961;43-A:185–192.
   PubMed Web of Science ®Google Scholar
• Owens C, Abbott LS, Gupta AA. Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy. Paediatr Drugs. 2013;15(6):473–492.
   PubMed Web of Science ®Google Scholar
• Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348(8):694–701.
   PubMed Web of Science ®Google Scholar
• Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30:4148–4154.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Valteau-Couanet D, Glogova E, et al. The role of megatherapy (MGT) and stem cell transplantation (SCT) in high risk Ewing tumors: more than 30 years of EBMT activity. Presented at the 27th Annual Meeting of the European Musculo- Skeletal Oncology Society; 2014 May 21–23; Vienna, Austria
   Google Scholar
• Marina N, Meyers P. High-dose therapy and stem-cell rescue for Ewing’s family of tumors in second remission. J Clin Oncol. 2005;23:4262–4264.
   PubMed Web of Science ®Google Scholar
• Loschi S, Dufour C, Oberlin O, et al. Tandem high-dose chemotherapy strategy as first-line treatment of primary disseminated multifocal Ewing sarcomas in children, adolescents and young adults. Bone Marrow Transplant. 2015;50:1083–1088.
   PubMed Web of Science ®Google Scholar
• Ladenstein R, Pötschger U, Le Deley MC, et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010;28:3284–3291.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Sundby HK, Luksch R, et al Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. Ann Oncol. 2011;22:1221–1227.
   PubMed Web of Science ®Google Scholar
• Mackintosh C, Ordóñez JL, García-Domínguez DJ, et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene. 2012;31:1287–1298.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Galindo C, Navid F, Liu T, et al. Prognostic factors for local and distant control in Ewing sarcoma family of tumors. Ann Oncol. 2008;19:814–820.
   PubMed Web of Science ®Google Scholar
• Saylors RL 3rd. Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19:3463–3469.
   PubMed Web of Science ®Google Scholar
• Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 2011;57:549–553.
   PubMed Web of Science ®Google Scholar
• Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2009;53:1029–1034.
   PubMed Web of Science ®Google Scholar
• Fox E, Patel S, Wathen JK, et al. Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003. Oncologist. 2012;17:e321–9.
   PubMed Web of Science ®Google Scholar
• Raciborska A, Bilska K, Drabko K, et al. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma. Pediatr Blood Cancer. 2013;60:1621–1625.
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Ichante JL, Nguyen L, et al. Phase II study of vinorelbine and continuous low doses cyclophosphamide in children and young adults with a relapsed or refractory malignant solid tumour: good tolerance profile and efficacy in rhabdomyosarcoma - a report from the Societe Francaise des Cancers et leucemies de l’Enfant et de l’adolescent (SFCE). Eur J Cancer. 2012;45:2409–2416.
   Web of Science ®Google Scholar
• Owens C, Laurence V, Benboubker L, et al. Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma. Cancer Chemother Pharmacol. 2013;71:399–404.
   PubMed Web of Science ®Google Scholar
• Martínez N, Sánchez-Beato M, Carnero A, et al. Transcriptional signature of ecteinascidin 743 (yondelis, trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther. 2005;4:814–823.
   PubMed Web of Science ®Google Scholar
• Grohar PJ, Segars LE, Yeung C, et al. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth. Clin Cancer Res. 2014;20:1190–1203.
   PubMed Web of Science ®Google Scholar
• Tancredi R, Zambelli A, DaPrada GA, et al. Targeting the EWS-FLI1 transcription factor in Ewing sarcoma. Cancer Chemother Pharmacol. 2015;75:1317–1320.
   PubMed Web of Science ®Google Scholar
• Baruchel S, Pappo A, Krailo M, et al. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children’s Oncology Group. Eur J Cancer. 2012;48:579–585.
   PubMed Web of Science ®Google Scholar
• Lau L, Supko JG, Blaney S, et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors: a Children’s Oncology Group study. Clin Cancer Res. 2005;11:672–677.
   PubMed Web of Science ®Google Scholar
• Owen LA, Kowalewski AA, Lessnick SL. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing’s sarcoma. PLoS One. 2008;3:e1965.
   PubMed Web of Science ®Google Scholar
• Garcia-Aragoncillo E, Carrillo J, Lalli E, et al. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing’s tumor cells. Oncogene. 2008;27:6034–6043.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan R, Fujimura Y, Zou JP, et al. Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1. Oncogene. 2004;23:7087–7094.
   PubMed Web of Science ®Google Scholar
• Matsunobu T, Tanaka K, Nakamura T, et al. The possible role of EWS-Fli1 in evasion of senescence in Ewing family tumors. Cancer Res. 2006;66:803–811.
   PubMed Web of Science ®Google Scholar
• Grohar PJ, Griffin LB, Yeung C, et al. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells. Neoplasia. 2011;13:145–153.
   PubMed Web of Science ®Google Scholar
• Boro A, Prêtre K, Rechfeld F, et al. Small‐molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing’s sarcoma. Int J Cancer. 2012;131:2153–2164.
   PubMed Web of Science ®Google Scholar
• Minas TZ, Han J, Javaheri T, et al. YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. Oncotarget. 2015;6:37678–37694.
   PubMed Web of Science ®Google Scholar
• Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, et al. An oral formulation of YK-4-279: preclinical efficacy and acquired resistance patterns in Ewing sarcoma. Mol Cancer Ther. 2015;14:1591–1604.
   PubMed Web of Science ®Google Scholar
• Mita MM, Mita AC, Chu QS, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol. 2008;26:361–367.
   PubMed Web of Science ®Google Scholar
• Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30:78–84.
   PubMed Web of Science ®Google Scholar
• Tap WD, Demetri G, Barnette P, et al. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012;30:1849–1856.
   PubMed Web of Science ®Google Scholar
• Schöffski P, Adkins D, Blay JY, et al. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer. 2013;49:3219–3228.
   PubMed Web of Science ®Google Scholar
• Naing A, LoRusso P, Fu S, et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing’s sarcoma family tumors. Clin Cancer Res. 2012;18:2625–2631.
   PubMed Web of Science ®Google Scholar
• Choy E, Butrynski JE, Harmon DC, et al. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014;14:813.
   PubMed Web of Science ®Google Scholar
• Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2008;26:399–405.
   PubMed Web of Science ®Google Scholar
• Chao J, Budd GT, Chu P, et al. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors. Anticancer Res. 2010;30:547–552.
   PubMed Web of Science ®Google Scholar
• Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;50:254–258.
   PubMed Web of Science ®Google Scholar
• Fox E, Aplenc R, Bagatell R, et al. A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors. J Clin Oncol. 2010;28:5174–5181.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Drissi R, Muscal JA, et al. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children’s Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res. 2013;19:6578–6584.
   PubMed Web of Science ®Google Scholar
• Amaral AT, Garofalo C, Frapolli R, et al. Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents. Clin Cancer Res. 2015;21:1373–1382.
   PubMed Web of Science ®Google Scholar
• Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing’s sarcoma cell proliferation. Oncogene. 2003;22:9282–9287.
   PubMed Web of Science ®Google Scholar
• Prieur A, Tirode F, Cohen P, et al EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004;24:7275–7283.
   PubMed Web of Science ®Google Scholar
• Ho AL, Schwartz GK. Targeting of insulin-like growth factor Type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? J Clin Oncol. 2011;29:4581–4583.
   PubMed Web of Science ®Google Scholar
• Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159–169.
   PubMed Web of Science ®Google Scholar
• Pappo AS, Vassal G, Crowley JJ, et al. A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014;120:2448–2456.
   PubMed Web of Science ®Google Scholar
• Garofalo C, Mancarella C, Grilli A, et al. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing’s sarcoma. Mol Endocrinol. 2012;26:1603–1616.
   PubMed Web of Science ®Google Scholar
• Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012;483:570–575.
   PubMed Web of Science ®Google Scholar
• Brenner JC, Feng FY, Han S, et al. PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res. 2012;72:1608–1613.
   PubMed Web of Science ®Google Scholar
• Wilcoxen KM, Brooks DG, Tiruchinapalli D, et al. The PARP inhibitor niraparib demonstrates synergy with chemotherapy in treatment of patient derived Ewing’s sarcoma tumorgraft models. Mol Cancer Ther. 2013;12(11 Suppl):abstr A258.
   Google Scholar
• Lee HJ, Yoon C, Schmidt B, et al. Combining PARP-1 inhibition and radiation in Ewing sarcoma results in lethal DNA damage. Mol Cancer Ther. 2013;12:2591–2600.
   PubMed Web of Science ®Google Scholar
• Schafer E. A phase 1/2 study of BMN 673, an oral poly(ADP-Ribose) polymerase inhibitor, plus temozolomide in children with refractory or recurrent malignancies. (Recruiting now, no results published). ID Number: NCI-2014-00804. NCT Identifier: NCT02116777.
   Google Scholar
• Demetri G. Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma (Recruiting now, no results published). NCT 01858168 (NCI-2013-01821)
   Google Scholar
• Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci U S A. 2003;100:7785–7790.
   PubMed Web of Science ®Google Scholar
• DuBois SG, Marina N, Glade-Bender J. Angiogenesis and vascular targeting in Ewing sarcoma: a review of preclinical and clinical data. Cancer. 2010;116:749–757.
   PubMed Web of Science ®Google Scholar
• Leavey P, Glade Bender JL, Mascarenhas L, et al. Feasibility of bevacizumab (NSC 704865, BB-IND #7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): a Children’s Oncology Group (COG) study. J Clin Oncol. 2010;28(15s):abstr 9552.
   Google Scholar
• Li X, Ponten A, Aase K, et al. PDGF-C is a new protease activated ligand for the PDGF alpha-receptor. Nat Cell Biol. 2000;2:302–309.
   PubMed Web of Science ®Google Scholar
• Gilbertson DG, Duff ME, West JW, et al. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem. 2001;276:27406–27414.
   PubMed Web of Science ®Google Scholar
• Merchant MS, Woo CW, Mackall CL, et al. Potential use of imatinib in Ewing’s sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst. 2002;94:1673–1679.
   PubMed Web of Science ®Google Scholar
• Morton CL, Maris JM, Keir ST, et al. Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;58:566–571.
   PubMed Web of Science ®Google Scholar
• Huang F, Hurlburt W, Greer A, et al. Differential mechanisms of acquired resistance to insulin-like growth factor-I receptor antibody therapy or to a small-molecule inhibitor BMS-754807, in a human rhabdomyosarcoma model. Cancer Res. 2010;70:7221–7231.
   PubMed Web of Science ®Google Scholar
• Fleuren ED, Versleijen-Jonkers YM, Boerman OC. van der Graaf WT. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: Current hurdles and future perspectives. Biochim Biophys Acta. 2014;1845:266–276.
   PubMed Web of Science ®Google Scholar
• Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015.
   PubMed Web of Science ®Google Scholar
• Proctor A, Brownhill SC, Burchill SA. The promise of telomere length, telomerase activity and its regulation in the translocation- dependent cancer ESFT; clinical challenges and utility. Biochim Biophys Acta. 2009;1792:260–274.
   PubMed Web of Science ®Google Scholar
• Avigad S, Naumov I, Ohali A, et al. Short telomeres: a novel potential predictor of relapse in Ewing sarcoma. Clin Cancer Res. 2007;13:5777–5783.
   PubMed Web of Science ®Google Scholar
• Islam AB, Richter WF, Lopez-Bigas N, et al. Selective targeting of histone methylation. Cell Cycle. 2011;10:413–424.
   PubMed Web of Science ®Google Scholar
• Popovic R, Licht JD. Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov. 2012;2:405–413.
   PubMed Web of Science ®Google Scholar
• Hormaeche I, Licht JD. Chromatin modulation by oncogenic transcription factors: new complexity, new therapeutic targets. Cancer Cell. 2007;11:475–478.
   PubMed Web of Science ®Google Scholar
• Sampson VB, Vetter NS, Kamara DF, et al. Vorinostat enhances cytotoxicity of SN-38 and temozolomide in Ewing sarcoma cells and activates STAT3/AKT/MAPK pathways. PLoS One. 2015;10. e0142704.
   PubMed Web of Science ®Google Scholar
• Sankar S, Theisen ER, Bearss J, et al. Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res. 2014;20:4584–4597.
   PubMed Web of Science ®Google Scholar
• Margulies BS, Damron TA, Allen MJ. The differential effects of the radioprotectant drugs amifostine and sodium selenite treatment in combination with radiation therapy on constituent bone cells, Ewing’s sarcoma of bone tumor cells, and rhabdomyosarcoma tumor cells in vitro. J Orthop Res. 2008;26:1512–1519.
   PubMed Web of Science ®Google Scholar
• Kubo T, Shimose S, Matsuo T, et al. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res. 2006;24:1138–1144.
   PubMed Web of Science ®Google Scholar
• Kovar H, Dworzak M, Strehl S, et al. Overexpression of the pseudoautosomal gene MIC2 in Ewing’s sarcoma and peripheral primitive neuroectodermal tumor. Oncogene. 1990;5:1067–1070.
   PubMed Web of Science ®Google Scholar
• Rocchi A, Manara MC, Sciandra M, et al. CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis. J Clin Invest. 2012;120:668–680.
   Web of Science ®Google Scholar
• Cerisano V, Aalto Y, Perdichizzi S, et al. Molecular mechanisms of CD99-induced caspase independent-cell death and cell–cell adhesion in Ewing’s sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene. 2004;23:5664–5674.
   PubMed Web of Science ®Google Scholar
• Hahn MJ, Yoon SS, Sohn HW, et al. Differential activation of MAP kinase family members triggered by CD99 engagement. FEBS Lett. 2000;470:350–354.
   PubMed Web of Science ®Google Scholar
• Byun HJ, Hong IK, Kim E, et al. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem. 2006;281:34833–34847.
   PubMed Web of Science ®Google Scholar
• Sohn HW, Choi EY, Kim SH, et al. Engagement of CD99 induces apoptosis through a calcineurin-independent pathway in Ewing’s sarcoma cells. Am J Pathol. 1998;153:1937–1945.
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Perdichizzi S, Bernard G, et al. Targeting CD99 in association with doxorubicin: an effective combined treatment for Ewing’s sarcoma. Eur J Cancer. 2006;42:91–96.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Fritsch G, Buchinger P, et al. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood. 1994;83:415–425.
   PubMed Web of Science ®Google Scholar
• Michel MD, Beck-Sickinger A, Cox H, et al. XVI International Union of Pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol Rev. 1998;50:143–150.
   PubMed Web of Science ®Google Scholar
• Li J, Tian Y, Wu A. Neuropeptide Y receptors promising target for cancer imaging and therapy. Regen Biomater. 2015;2:215–219.
   PubMedGoogle Scholar
• Li J, Shen Z, Ma X, et al. Neuropeptide Y Y1 receptors meditate targeted delivery of anticancer drug with encapsulated nanoparticles tobreast cancer cells with high selectivity and its potential for breast cancer therapy. ACS Appl Mater Interfaces. 2015;7:5574–5582.
   PubMed Web of Science ®Google Scholar
• Körner M, Waser B, Reubi JC. High expression of neuropeptide Y1 receptors in Ewing sarcoma tumors. Clin Cancer Res. 2008;14:5043–5049.
   PubMed Web of Science ®Google Scholar